Assertio (ASRT)
(Delayed Data from NSDQ)
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Ensign Group (ENSG) Rises 30% in 6 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for improvement on growing revenues derived from catering to patients under Medicaid and Medicare programs. Solid cash flows are other tailwinds.
Is Assertio (ASRT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
After Golden Cross, Assertio (ASRT)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
ASRT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.
Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
by Zacks Equity Research
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Should Value Investors Buy Assertio (ASRT) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks
by Zacks Equity Research
Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
by Zacks Equity Research
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?
by Zacks Equity Research
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Tyvaso drive the top line in the quarter.
Assertio (ASRT) Stock Moves -1.12%: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.65, moving -1.12% from the previous trading session.
Are Investors Undervaluing Assertio (ASRT) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Assertio (ASRT) Stock Moves -0.41%: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $2.45, marking a -0.41% move from the previous day.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.